Rabies Vaccination and Immunotherapy
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against Infectious Diseases".
Deadline for manuscript submissions: closed (20 August 2022) | Viewed by 5482
Special Issue Editor
Interests: rabies virus; immunopathology; immune evasion; vaccines; antibodies; antivirals
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Although rabies virus is nearly 100% fatal once clinical signs develop, it is also a vaccine-preventable disease. However, multiple factors have impeded successful and widespread administration of rabies vaccines and immunotherapies, including expense and the need for cold chain storage in areas that are remote and may lack reliable electricity. Additionally, vaccines and immunotherapies for rabies virus need to demonstrate high efficacy given the potential for a fatal outcome in untreated or inadequately treated individuals exposed to rabies virus.
The goal of this Special Issue is to feature manuscripts addressing the advancements in the treatment and prevention of rabies infection, including but not limited to developing effective rabies vaccines, novel therapeutics, antiviral response, animal models, and delivery methods. Research articles that describe prevention and potential treatment for lyssavirus phylogroups II and III are also welcome.
Dr. April D. Davis
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Rabies
- Vaccine
- Antibodies
- Post-exposure prophylaxis
- Host response
- Animal model
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
